Jane Street
TSHA icon

Jane Street’s Taysha Gene Therapies TSHA Stock Holding History

Jane Street’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-163,146
Closed -$759K – 13011
2025
Q4 		$897K Sell
163,146
-393,639
-71% -$1.91M ﹤0.01% 6345
2025
Q3 		$1.82M Buy
556,785
+419,791
+306% +$1.19M ﹤0.01% 5109
2025
Q2 		$316K Buy
+136,994
New +$298K ﹤0.01% 7763
2025
Q1 		– Sell
-169,575
Closed -$293K – 10630
2024
Q4 		$293K Buy
169,575
+62,003
+58% +$129K ﹤0.01% 7774
2024
Q3 		$216K Sell
107,572
-20,552
-16% -$45.1K ﹤0.01% 8545
2024
Q2 		$287K Buy
128,124
+69,238
+118% +$201K ﹤0.01% 7871
2024
Q1 		$169K Buy
58,886
+16,608
+39% +$34.6K ﹤0.01% 8274
2023
Q4 		$74.8K Buy
+42,278
New +$84.3K ﹤0.01% 8680
2020
Q4 		– Sell
-23,234
Closed -$520K – 8118
2020
Q3 		$520K Buy
+23,234
New +$547K ﹤0.01% 5089

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's TSHA Position: Q1 2026 in Review

Jane Street sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 163,146 shares — an estimated $759K sold.

Jane Street first reported a position in TSHA in Q3 2020 and held it in 9 quarters. The position peaked at $1.82M in Q3 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Jane Street reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 163,146 Taysha Gene Therapies shares in Q1 2026, an estimated $759K.
  • Jane Street first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 9 quarters.
  • Jane Street's Taysha Gene Therapies position peaked at $1.82M in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.